HR 1532 · in committee · niche
Scientific EXPERT Act of 2025
- healthcare
What this bill does
- The FDA must work with the Reagan-Udall Foundation to hold science-focused meetings on rare disease drug development at least four times yearly.
- Drug companies, medical experts, patient organizations, and FDA officials participate in these meetings to align on treatment development questions.
- The foundation establishes a steering committee to select topics and publishes summaries after each meeting; the FDA reports whether it used input when approving drugs.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might holding structured FDA meetings four times yearly on rare disease drugs change the speed or cost of bringing treatments to patients?
- 02
What accountability mechanisms exist if the FDA receives input from these meetings but doesn't incorporate it into drug approval decisions?
- 03
Which stakeholders—drug companies, patients, or medical experts—might benefit most or face the most burden from participating in these mandatory meetings?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-CA-7
Doris O. Matsui
Citizen cosponsors
0
In Congress
2/ 435
House Reps cosponsoring
Introduced 2025-02-24
Joining the bill
Legislative timeline
2025-02-24 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-02-24 · IntroReferral
Introduced in House
2025-02-24 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.